分红方面，理邦仪器A股上市后累计派现11.28亿元。近三年，累计派现3.60亿元。 机构持仓方面，截止2025年9月30日，理邦仪器十大流通股东中，香港中央结算有限公司位居第一大流 通股东，持股3386.87万股，相比上期减少309.93万股。医疗器械ETF（159883）位居第九大流通股东， 持股178.76万股，为新进股东。博道远航混合A（007126）位居第十大流通股东，持股167.37万股，为 新进股东。招商量化精选股票发起式A（001917）退出十大流通股东之列。 理邦仪器所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：互联医疗、小盘、多胎 概念、养老产业、医疗器械等。 截至11月10日，理邦仪器股东户数2.35万，较上期减少3.61%；人均流通股14407股，较上期增加 3.74%。2025年1月-9月，理邦仪器实现营业收入14.46亿元，同比增长4.63%；归母净利润2.57亿元，同 比增长49.29%。 11月27日，理邦仪器盘中上涨2.04%，截至13:03，报14.01元/股，成交7579.30万元，换手率1.63%，总 市值81.21亿元。 资金流向方面，主力资金净流入5 ...

Core Viewpoint - WanDong Medical's stock price has shown a mixed performance in recent trading sessions, with a year-to-date increase of 10.02% and a recent decline over the past 60 days [1][2]. Group 1: Stock Performance - As of November 27, WanDong Medical's stock price increased by 2.04%, reaching 16.47 CNY per share, with a total market capitalization of 11.579 billion CNY [1]. - The stock has experienced a trading volume of 69.7167 million CNY, with a turnover rate of 0.61% [1]. - Year-to-date, the stock has risen by 10.02%, with a slight increase of 0.43% over the last five trading days, a 5.17% increase over the last 20 days, and a decline of 7.05% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, WanDong Medical reported a revenue of 1.189 billion CNY, reflecting a year-on-year growth of 8.73% [2]. - The company recorded a net profit attributable to shareholders of -27.2098 million CNY, representing a year-on-year decrease of 123.51% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for WanDong Medical increased to 27,200, up by 1.23% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 1.22% to 25,882 shares [2]. - The company has distributed a total of 769 million CNY in dividends since its A-share listing, with 267 million CNY distributed over the past three years [3]. Group 4: Institutional Holdings - As of September 30, 2025, the third-largest circulating shareholder is HuaBao ZhongZheng Medical ETF, holding 11.9198 million shares, a decrease of 2.0986 million shares from the previous period [3]. - The fifth-largest shareholder is Hong Kong Central Clearing Limited, which increased its holdings by 2.5364 million shares to 7.0349 million shares [3]. - The tenth-largest shareholder is NanFang ZhongZheng 1000 ETF, holding 3.8619 million shares, a decrease of 31,900 shares from the previous period [3].

来源：新浪证券-红岸工作室 11月26日，采纳股份涨0.04%，成交额5969.26万元，换手率3.00%，总市值31.81亿元。 异动分析 辅助生殖+医疗器械概念+人民币贬值受益 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额2708.33万，占总成交额的7.73%。 技术面：筹码平均交易成本为27.79元 1、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 2、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入374.99万，占比0.06%，行业排名19/132，连续3日被主力资金增仓；所属行业主力净流 入-3.74亿，连续2日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入374.99万1461.35万666.29万-1893.98万906.73万 该股筹码平均交易成本为27.79元，近期筹码快速出 ...

资金流向方面，主力资金净流出158.09万元，特大单买入0.00元，占比0.00%，卖出101.47万元，占比 2.64%；大单买入696.40万元，占比18.12%，卖出753.01万元，占比19.59%。 昊海生科今年以来股价跌17.01%，近5个交易日跌1.55%，近20日跌2.29%，近60日跌13.06%。 11月26日，昊海生科盘中下跌2.00%，截至14:11，报49.46元/股，成交3844.25万元，换手率0.40%，总 市值115.03亿元。 机构持仓方面，截止2025年9月30日，昊海生科十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股560.48万股，相比上期增加261.70万股。 责任编辑：小浪快报 截至9月30日，昊海生科股东户数8388.00，较上期增加7.44%；人均流通股0股，较上期增加0.00%。 2025年1月-9月，昊海生科实现营业收入18.99亿元，同比减少8.47%；归母净利润3.05亿元，同比减少 10.63%。 分红方面，昊海生科A股上市后累计派现8.91亿元。近三年，累计派现5.57亿元。 资料显示，上海昊海生物科技股份有限公司位于上海市长宁区虹 ...

华熙生物所属申万行业为：美容护理-医疗美容-医美耗材。所属概念板块包括：化妆品、生物制造、医 疗器械、基金重仓、增持回购等。 截至11月20日，华熙生物股东户数3.01万，较上期减少0.62%；人均流通股16014股，较上期增加 0.62%。2025年1月-9月，华熙生物实现营业收入31.63亿元，同比减少18.36%；归母净利润2.52亿元，同 比减少30.29%。 分红方面，华熙生物A股上市后累计派现11.38亿元。近三年，累计派现5.28亿元。 机构持仓方面，截止2025年9月30日，华熙生物十大流通股东中，易方达上证科创板50ETF（588080） 位居第三大流通股东，持股696.42万股，相比上期减少101.36万股。华夏上证科创板50成份ETF （588000）位居第四大流通股东，持股681.95万股，相比上期减少382.34万股。华宝中证医疗ETF （512170）位居第七大流通股东，持股537.40万股，相比上期减少105.90万股。南方中证500ETF （510500）位居第八大流通股东，持股287.49万股，相比上期减少4.80万股。香港中央结算有限公司位 居第九大流通股东，持股267.6 ...

樊鑫于2023年8月开始接管融通多元收益一年持有期混合基金，2025年2月份，该基金新增两位基金经理石础、李皓，与樊鑫共同管理该基金。其中，李皓现 任融通基金固定收益研究部副总经理（主持工作）。 融通多元收益一年持有期混合基金成立于2021年8月3日，刚成立时的净认购金额约为3.50亿元，到了2025年三季度末，资产净值约为0.15亿元。 11月21日，融通基金发布公告称，基金经理樊鑫因公司内部调整离任融通多元收益一年持有期混合基金。 | 离任基金经理姓名 | 樊雲 | | --- | --- | | 离任原因 | 内部调整 | | 离任日期 | 2025年11月21日 | | 转任本公司其他工作岗位的说明 | | 截至三季度末，融通多元收益一年持有期混合基金持有股票占比为25.55%，持有债券占比为65.48%，共持有8只股票，分别为江山股份、鸿远电子、航发动 力、温氏股份、兴发集团、学大教育、明阳智能、扬农化工。 融通多元收益一年持有期混合基金三季报显示，三季度，该基金保持较高股票仓位，对组合进行部分调整，减持部分养殖、顺周期消费，加配半导体、军工 电子、农药、医疗器械、风电。 风险提示：观点仅供参考，不 ...

截至9月30日，春立医疗股东户数6164.00，较上期增加4.12%；人均流通股46906股，较上期减少 3.95%。2025年1月-9月，春立医疗实现营业收入7.56亿元，同比增长48.75%；归母净利润1.92亿元，同 比增长213.21%。 分红方面，春立医疗A股上市后累计派现3.59亿元。近三年，累计派现3.09亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 春立医疗今年以来股价涨95.67%，近5个交易日跌3.14%，近20日跌3.11%，近60日涨10.45%。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京 ...

Core Viewpoint - Tiger Med's stock price has shown a decline of 4.42% year-to-date, with significant drops over various trading periods, indicating potential challenges in the market [1][2]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion yuan [2]. - Cumulative cash dividends since the A-share listing amount to 2.458 billion yuan, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.01% to 48,400, with an average of 0 shares per shareholder [2]. - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and other notable funds such as China Europe Medical Health Mixed A and Huabao CSI Medical ETF [3]. Market Activity - On November 26, Tiger Med's stock rose by 2.08% to 51.92 yuan per share, with a trading volume of 154 million yuan and a turnover rate of 0.53% [1]. - The stock has experienced a net inflow of 8.478 million yuan from major funds, with significant buying and selling activity noted [1]. Business Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV of clinical trials [1]. - The company's revenue composition includes 52.60% from clinical trial-related services and 45.21% from clinical trial technical services [1]. Industry Classification - Tiger Med is classified under the pharmaceutical and biological sector, specifically in medical services and medical research outsourcing [2]. - The company is associated with various concept sectors, including mid-cap, margin financing, social security heavy positions, medical devices, and internet healthcare [2].

Core Viewpoint - Jinhua Co., Ltd. has experienced a stock price increase of 13.08% year-to-date, with significant gains in recent trading periods, indicating positive market sentiment despite a slight decline on November 26 [2]. Group 1: Stock Performance - As of November 26, Jinhua's stock price was reported at 8.80 CNY per share, with a trading volume of 77.9 million CNY and a turnover rate of 2.34%, resulting in a total market capitalization of 3.285 billion CNY [1]. - The stock has seen a price increase of 8.51% over the last five trading days, 16.87% over the last 20 days, and 11.39% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Jinhua achieved a revenue of 384 million CNY, reflecting a year-on-year decrease of 8.36%, while the net profit attributable to shareholders was 34.48 million CNY, showing a year-on-year increase of 12.06% [2]. - The company's main business revenue is derived from pharmaceutical sales, accounting for 99.71% of total revenue, with other income contributing 0.29% [2]. Group 3: Shareholder Information - As of September 30, the number of shareholders for Jinhua was 20,100, a decrease of 2.22% from the previous period, with an average of 18,574 circulating shares per shareholder, which is an increase of 2.27% [2]. Group 4: Dividend Information - Since its A-share listing, Jinhua has distributed a total of 118 million CNY in dividends, with 10.58 million CNY distributed over the past three years [3].

Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has experienced a decline of 15.47% year-to-date, with a slight recovery observed on November 25, where it rose by 2.13% to reach 50.38 CNY per share, indicating potential market interest despite recent downturns [2][1]. Company Overview - Haohai Biological Technology, established on January 24, 2007, and listed on October 30, 2019, is located in Shanghai and specializes in the research, production, and sales of medical devices and pharmaceuticals [2]. - The company's revenue composition includes: 44.12% from medical beauty and wound care products, 28.18% from ophthalmic products, 17.39% from orthopedic products, 8.46% from anti-adhesion and hemostatic products, and 1.86% from other products [2]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion CNY, reflecting a year-on-year decrease of 8.47%, while the net profit attributable to shareholders was 305 million CNY, down 10.63% year-on-year [2]. - The company has distributed a total of 891 million CNY in dividends since its A-share listing, with 557 million CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 7.44% to 8,388, with an average of 0 shares held in circulation per shareholder [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 5.6048 million shares, an increase of 2.617 million shares compared to the previous period [3]. Market Activity - On November 25, the stock saw a trading volume of 31.1529 million CNY, with a turnover rate of 0.32%, and a net inflow of main funds amounting to 1.7261 million CNY [1].